In Patients With Hip Dysplasia, Mid-Term Lower Extremities and Spine After Hip Arthroplasty Natural Course

March 26, 2025 updated by: Bezmialem Vakif University

In Patients With Crowe Type III and Crowe Type IV Hip Dysplasia, Mid-Term Lower Extremities and Spine After Total Hip Arthroplasty Natural Course

Patients with developmental hip dysplasia often present to the outpatient clinic in adulthood with hip pain due to progressive hip osteoarthritis. However, they may have complaints such as limping, lumbar lordosis, lower back pain, and leg length difference. Today, the best treatment option for these patients is hip arthroplasty. Hip arthroplasty causes a high rate of functional improvement and pain relief. According to the hip arthroplasty technique applied, improvement in lameness, leg length difference and spinal curvatures is expected. The aim of our study is to show the change in postoperative spine and lower extremity curvatures after hip arthroplasty in patients with advanced developmental hip dislocation.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Developmental hip dysplasia (DDH) describes the spectrum of anatomical changes in the acetabulum and proximal femur; these can cause limping, lower back pain, lumbar lordosis, and leg length variation. DDH is the main cause of degenerative arthritis of the hip and valgus deformity of the knee. The best treatment option for DDH is total hip arthroplasty (THA). During THA, the distorted anatomy of the acetabulum and proximal femur poses great difficulties. Additionally, the soft tissue can be released and the femur can be shortened while correcting the placement of the acetabulum to prevent neurological damage (sciatic nerve paralysis). Postoperative evaluations focused on assessing joint function and alleviating preoperative clinical symptoms. Some studies have examined changes in lower extremity and knee alignment after THA in patients with DDH. In patients with DDH, THA may cause genu valgus deformity due to increased lower extremity length and Q angle immediately after the operation. THA extends the lower extremity, affecting the patellofemoral joint and anterior knee pain. However, the long-term effects of THA on the alignment of the lower extremity are unclear, especially in patients with Crowe type III and IV DDH, which involves femoral shortening osteotomy. There are few studies examining changes in the knee and lower extremities as a result of THA in patients with DDH. The aim of this study is to evaluate the mid- and long-term alignment of the spine and lower extremity after THA with or without femoral shortening osteotomy in patients with unilateral DDH (Crowe type III-IV).

Study Type

Interventional

Enrollment (Actual)

33

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Fatih
      • Istanbul, Fatih, Turkey, 34093
        • Bezmialem Vakıf University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patients with unilateral Crowe type 3 hip dysplasia
  2. Patients with unilateral Crowe type 4 hip dysplasia

Exclusion Criteria:

  1. Patients with unilateral Crowe type 1 hip dysplasia
  2. Patients with unilateral Crowe type 2 hip dysplasia
  3. History of previous surgery on the hip for which surgery is planned

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent total hip replacement
Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mechanical axis deviation (MAD)
Time Frame: From enrollment to the end of treatment at 2 years
the lower limb was defined as the distance from the center of the knee to the mechanical axis of the lower limb
From enrollment to the end of treatment at 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
tibiofemoral angle (TFA)
Time Frame: From enrollment to the end of treatment at 2 years
the angle formed by the line from the center of the femoral canal to the center of the knee joint and the line from the center of the knee joint to the center of the ankle joint.
From enrollment to the end of treatment at 2 years
The femoral offset (FO)
Time Frame: From enrollment to the end of treatment at 2 years
the vertical distances from the center of the femoral head to the center of the femoral canal
From enrollment to the end of treatment at 2 years
The hip-knee-ankle angle (HKA)
Time Frame: From enrollment to the end of treatment at 2 years
the angle formed by the mechanical axis of the femur and the mechanical axis of the tibia
From enrollment to the end of treatment at 2 years
The lateral distal femoral angle (LDFA)
Time Frame: From enrollment to the end of treatment at 2 years
the angle formed by the anatomic axis of the femur and the distal femoral joint orientation line
From enrollment to the end of treatment at 2 years
The medial proximal tibial angle (MPTA)
Time Frame: From enrollment to the end of treatment at 2 years
the angle formed by the anatomic axis of the tibia and the proximal tibial joint orientation line
From enrollment to the end of treatment at 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2021

Primary Completion (Actual)

November 15, 2023

Study Completion (Actual)

October 1, 2024

Study Registration Dates

First Submitted

December 10, 2023

First Submitted That Met QC Criteria

December 10, 2023

First Posted (Actual)

December 19, 2023

Study Record Updates

Last Update Posted (Actual)

April 1, 2025

Last Update Submitted That Met QC Criteria

March 26, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I do not think it is right that the data of the patients in the study can be seen by everyone.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Total Hip Arthroplasty

Clinical Trials on total hip arthroplasty

Subscribe